CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 623 enrolled
Drug / intervention
fluticasone furoate/vilanterol 100/25mcg +1 moredrug
Likely dose
fluticasone furoate/vilanterol 100/25mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01627327
NCT01627327Phase 3Completed

A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once-Daily Via a Novel Dry Powder Inhaler Compared With Tiotropium Bromide Inhalation Powder 18mcg Delivered Once-Daily Via the HandiHaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Who Have or Are at Risk for Co-morbid Cardiovascular Disease

GlaxoSmithKline·interventional·Posted Jun 25, 2012·Updated Nov 9, 2017

In Brief

A Phase 3 clinical trial evaluating fluticasone furoate/vilanterol 100/25mcg and tiotropium bromide 18mcg for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 623 participants across 54 sites in 6 countries.

Detailed Summary

The purpose of this study is to evaluate the 24-hour spirometry effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg once daily compared with tiotropium bromide inhalation powder 18mcg once daily over a 12-week treatment period in subjects with COPD who have or are at risk for co-morbid cardiovascular disease

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, Czechia, Germany, Poland, Romania, United States
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJun 25, 2012
Enrollment StartApr 1, 2012
Primary CompletionDec 1, 2012
Study CompletionDec 21, 2012
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 14.0 years ago

Interventions

fluticasone furoate/vilanterol 100/25mcgdrug

inhalation powder

tiotropium bromide 18mcgdrug

inhalation powder